Skip to main content
close menu
close menu

Search UK HealthCare

B. Mark Evers, MD, FACS

Director, Markey Cancer Center
Director, Markey Cancer Center Affiliate Network
Physician in Chief of Oncology Service
Vice Dean for Academic Development, College of Medicine
Vice-Chair for Research, Department of Surgery
Dr. Mark Evers
best doctor logo

Practice Area

  • General Surgery
  • Melanoma (Skin Cancer) Team
  • Surgical Oncology
  • Thyroid Cancer Team
Request an Appointment Physician Referral
  • About

    Faculty Rank

    Professor of Surgery


    University of Tennessee Health Science Center, Memphis


    University of Louisville, School of Medicine


    University of Texas Medical Branch, Galveston

    Certifications and Special Training

    American Board of Surgery

  • Publications


    1. p27Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells. Wang QD, Zhou Y, Wang XF, Evers BM. Cell Death & Differentiation 15:908-919, 2008.
    2. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Rychahou PG, Kang J, Gulhati P, Doan H, Chen AL, Xiao S, Chung DH, Evers BM. Proceedings of the National Academy of Sciences 105:20315-20320, 2008.
    3. mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O’Connor KL, Gao T, Evers BM. Cancer Research 71:3246-3256, 2011.
    4. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O’Connor KL, Morris AJ, Sunkara M, Weiss HL, Lee EY, Evers BM. Cancer Research 72:1504-1517, 2012.
    5. The PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport. Li J, Song J, Cassidy M, Rychahou P, Starr M, Liu J, Li X, Epperly G, Weiss HL, Townsend C, Gao T, Evers BM. Molecular Endocrinology 26:1380-1393, 2012.
  • Clinical Interests

    • Gastrointestinal Cancer
    • Gastrointestinal Physiology and Endocrinology
    • Gastrointestinal Surgery
    • Molecular Mechanisms of Normal Intestinal Development
    • Surgical Oncology
  • Research

    Cancer Center Member

    Research Focus

    Dr. Evers’s basic research, continuously funded by the NIH for the past 21, years focuses on signaling pathways regulating colorectal cancer proliferation and metastasis and mechanisms contributing to intestinal cell differentiation and aging.  

    His laboratory has identified key components of the PI3K/Akt/mTOR pathway which play differential roles in colorectal carcinogenesis and differentiation.  Activation of phosphatidylinositol 3-kinase (PI3K), a ubiquitous lipid kinase composed of an 85 kDa regulatory subunit (p85) and a 110 kDa catalytic subunit (p110) and its downstream effector protein, Akt, is associated with the growth and progression of a number of cancers, including colorectal cancer. Dr. Evers’s group hypothesizes that colorectal cancer growth and progression are augmented by increased p85α and Akt2 expression and that selective inhibition of PI3K/Akt components can suppress colorectal cancer growth and metastasis and can sensitize resistant colorectal cancers to chemotherapeutic agents.  

    Dr. Evers is the PI of an NIH MERIT award (R37 AG010885) which is focused on a better understanding of the function of the gut peptide neurotensin (NT) an important regulatory and trophic hormone localized to specialized enteroendocrine cells (N cells) of the adult small bowel.  

    Using the novel endocrine cell line model, BON, investigators in Dr. Evers’s laboratory have identified the signaling pathways responsible for NT secretion.  Current studies are also focused on the effects of NT associated with aging and on the proliferation of various cancers.  Dr. Evers is the PI of an R01 from NIDDK (R01 DK048498) which has led to the discovery of new pathways contributing to intestinal cell differentiation.  

    Current studies are analyzing unique interactions of mTOR on other signaling proteins such as the sirtuin family of proteins.  Finally, Dr. Evers is the PI for the UK GI Cancer SPORE planning grant (P20) which represents a multidisciplinary effort to identify better treatment, diagnostic and preventive strategies for GI cancers, a significant problem in Kentucky.  One project which is being performed in collaboration with Dr. Tianyan Gao is focused on colorectal cancer cell metabolism and effects of mTOR signaling.


    • Cancer Cell Biology and Signaling

    College & Department

    • College of Medicine
    • Department of Surgery

    For Referring Physicians

    Markey Cancer Center

    800 Rose St.
    Lexington, KY 40536
    United States